Publications by authors named "Keith Flaherty"

Claim this Profile
I
Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K.
Carolyn K McCourt, Zihan Wei, Kevin Kalinsky, Robert Gray, Victoria Wang, Keith T Flaherty

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Outcomes of Adjuvant Therapy in Stage III Melanoma and the Impact of Somatic Mutations.
Derek Effiom, Tyler Aprati, Anastasios Karneris, Aleigha Lawless, Tatyana Sharova, Keith Flaherty

Cancer Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The rise of new targets in melanoma.
Xue Bai, Keith T Flaherty

Br J Dermatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retraction Note: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.
Amanpreet Kaur, Marie R Webster, Katie Marchbank, Reeti Behera, Abibatou Ndoye, Keith T Flaherty

Nature· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Melanoma to rhabdomyosarcoma plasticity in the setting of immunotherapy.
Andrew D Knight, Emily J Robitschek, Jia-Ren Lin, Dennie T Frederick, Alvin Shi, Keith T Flaherty

medRxiv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymphotoxin-driven cancer cell eradication by tumoricidal CD8 TIL.
Hongyan Xie, Aiping Jiang, Aonkon Dey, Joseph W Dean, Jonathan J Perera, Keith T Flaherty

bioRxiv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131).
Mohamed A Gouda, Filip Janku, Ying Yuan, Leylah M Drusbosky, Alice P Chen, Keith T Flaherty

Clin Cancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Vismodegib in Patients With or -Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.
Anne S Tsao, Zihe Song, Alan L Ho, Janice M Mehnert, Percy Ivy, Keith T Flaherty

JCO Precis Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial.
Linda K Zane, Laura M Yee, Ting-Chia Chang, Jeffrey Sklar, Guangxiao Yang, Keith T Flaherty

Clin Cancer Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction of TRAIL-Induced Mcl-1 and cIAP2 by c-Myc or Sorafenib Sensitizes Resistant Human Cancer Cells to TRAIL-Induced Death.
M Stacey Ricci, Seok-Hyun Kim, Kazuhiro Ogi, John P Plastaras, Jianhua Ling, Keith T Flaherty

Cancer Cell· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PIK3CB Inhibitor GSK2636771 in Cancers With Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
Filip Janku, Opeyemi A Jegede, Shannon L Puhalla, Panagiotis A Konstantinopoulos, Funda Meric-Bernstam, Keith T Flaherty

JCO Precis Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Facts and Hopes: Toward the Next Quantum Leap in Melanoma.
Keith T Flaherty, Andrew E Aplin, Michael A Davies, Nir Hacohen, Meenhard Herlyn

Clin Cancer Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma.
Kelsey R Monson, Robert Ferguson, Joanna E Handzlik, Leah Morales, Jiahan Xiong, Keith T Flaherty

Nat Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming resistance to immunotherapy by targeting CD38 in human tumor explants.
Or-Yam Revach, Angelina M Cicerchia, Ofir Shorer, Claire A Palin, Boryana Petrova, Keith T Flaherty

Cell Rep Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of POLARIS: a study to look at different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis.
Alexander M Menzies, Georgina V Long, Amiee Kohn, Hussein Tawbi, Jeffrey Webe, Keith Flaherty

Future Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the COVID-19 Pandemic Mitigation Strategies on Cancer Treatment Trials: A Meta-Analysis of Industry and National Cancer Institute Studies.
Joseph M Unger, Hillary S Andrews, Laura A Levit, Brittany A McKelvey, Mark Stewart, Keith Flaherty

JCO Oncol Adv· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial Expression of Concern: A melanocyte lineage program confers resistance to MAP kinase pathway inhibition.
Cory M Johannessen, Laura A Johnson, Federica Piccioni, Aisha Townes, Dennie T Frederick, Keith T Flaherty

Nature· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids.
Yi Sun, Luke Maggs, Apekshya Panda, Samuel J Wright, Angelina M Cicerchia, Keith T Flaherty

Cancer Immunol Res· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma.
Dirk Schadendorf, Reinhard Dummer, Keith T Flaherty, Caroline Robert, Ana Arance

Future Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H.
Mohamed A Gouda, Zihan Wei, Jordi Rodon, Michael A Davies, Filip Janku, Keith T Flaherty

JCO Precis Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C.
Mark H O'Hara, Opeyemi Jegede, Mark A Dickson, Angela M DeMichele, Richard Piekarz, Keith T Flaherty

Clin Cancer Res· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Sunitinib in Tumors With Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V.
Lilian T Gien, Zihe Song, Andrew Poklepovic, Eric A Collisson, James A Zwiebel, Keith T Flaherty

JCO Precis Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Defactinib (VS6063) in Patients With Tumors With Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U.
Marjorie G Zauderer, Opeyemi Jegede, David M Jackman, James A Zwiebel, Robert J Gray, Keith T Flaherty

JCO Precis Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma.
Giuseppe Tarantino, Cora A Ricker, Annette Wang, William Ge, Tyler J Aprati, Keith T Flaherty

Sci Adv· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of the mRNA decapping enzyme scavenger (DCPS) inhibitor RG3039 on glioblastoma.
Hao Duan, Yuan Xie, Suwen Wu, Guangyin Zhao, Zhen Zeng, Keith T Flaherty

J Transl Med· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis